Today, 55 million people worldwide live with dementia, and approximately 70% of those cases are due to Alzheimer’s disease. Experts predict that this number will almost triple by 2050, which will be a huge burden on global healthcare systems. A recent series in The Lancet discusses the progress made in Alzheimer’s research, which is promising but at the same time shows that the healthcare system requires urgent adaptation.
Research is focused on how early diagnostics and new disease-modifying drugs (DMDs) are transforming Alzheimer’s treatment standards. Ten years ago, an accurate diagnosis was only possible after death. Now, blood tests based on biomarkers like p-Tau 217 allow us to detect Alzheimer’s disease even before symptoms appear. New medications are also available – lecanemab and donanemab – which fight amyloid plaques, the main cause of disease progression.
Early diagnosis and treatment give us a chance to slow the progression of the disease and significantly improve the quality of life for millions of patients. But this success depends on whether the healthcare system can adapt—overloaded memory clinics must be streamlined, service coordination must be improved, and diagnostic tools must be made accessible.
p-Tau 217 blood tests (approved by the FDA) enable early and large-scale screening, replacing invasive and expensive methods (e.g., lumbar puncture, PET scans). Since biomarkers can identify at-risk asymptomatic individuals, specialized brain health services are emerging that evaluate modifiable risk factors and offer interventions tailored to individual needs.
Unfortunately, many memory clinics are overloaded and understaffed. This also burdens referral systems, which creates long waiting lists. To meet the growing demands, coordination of services is essential, involving primary care providers, hospitals, and social services.
New disease-modifying therapies require intravenous infusions and constant monitoring with MRI (due to side effects). Currently, only a small number of patients meet the treatment criteria. At the same time, the effective management of behavioral and psychological symptoms, which greatly affects patients and caregivers, remains crucial. Unfortunately, despite the significant impact on quality of life, many patients still do not receive adequate symptomatic treatment.
The emotional and physical burden placed on caregivers, mostly women, often goes unnoticed. The largest part of the global cost associated with dementia comes from informal care. For complete Alzheimer’s management, caregiver support is essential through education, respite programs, and integrated care models.
Healthcare systems face a serious challenge. Models for oncology and multiple sclerosis confirm that integrated approaches, multidisciplinary teams, and rapid diagnostic centers improve outcomes. Alzheimer’s care requires the development of similar infrastructure. It is necessary to adopt innovative reimbursement models that will encourage the coordination of treatment, rather than the quantitative growth of services.
While safer and more effective drugs are in the development process, the healthcare system’s readiness is a priority. Investment is needed in both the implementation of innovative treatment and the creation of sustainable and equitable medical service systems for Alzheimer’s.
Source: The Lancet
